Headquarters
Japan

Hirotsu Bio Science

Biological diagnostics deliver a high level of sensitivity by leveraging biology, surpassing the sensitivity of artificial devices, while enabling costs to be kept low by selecting organisms that cost nothing for upkeep. Hirotsu Bio Science is working on the practical use of the world’s first-ever biological diagnosis, a cancer test known as N-NOSE. The test uses urine samples and is therefore non-invasive and simple, combining benefits including high sensitivity, low costs and early detection. It launched the commercial service of N-NOSE in January 2020 in Japan. In 2022, it developed and launched the world’s first pancreatic cancer test using genetic manipulation technology.

访问 Hirotsu Bio Science 网站

关于我们

  • 我们的任务
  • 我们的历史
  • 领导团队
  • 影响力

加入我们

快捷链接

语言版本

隐私政策和服务条款

站点地图

© 2025 世界经济论坛